NNNN Fundamental Analysis - ANBIO BIOTECHNOLOGY LTD

Fundamental Rating

Taking everything into account, NNNN scores 6 out of 10 in our fundamental rating. NNNN was compared to 555 industry peers in the Biotechnology industry. NNNN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NNNN is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

NNNN had positive earnings in the past year.

In the past year NNNN had a positive cash flow from operations.

1.2 Ratios

The Return On Assets of NNNN (19.95%) is better than 97.30% of its industry peers.

The Return On Equity of NNNN (21.95%) is better than 96.76% of its industry peers.

The Return On Invested Capital of NNNN (15.54%) is better than 96.76% of its industry peers.

NNNN had an Average Return On Invested Capital over the past 3 years of 27.94%. This is significantly above the industry average of 14.78%.

The 3 year average ROIC (27.94%) for NNNN is well above the current ROIC(15.54%). The reason for the recent decline needs to be investigated.

		Industry Rank	Sector Rank
ROA	19.95%
ROE	21.95%
ROIC	15.54%

ROA(3y)32.84%

ROA(5y)N/A

ROE(3y)36.27%

ROE(5y)N/A

ROIC(3y)27.94%

ROIC(5y)N/A

1.3 Margins

NNNN's Profit Margin of 38.63% is amongst the best of the industry. NNNN outperforms 98.38% of its industry peers.

NNNN's Profit Margin has declined in the last couple of years.

Looking at the Operating Margin, with a value of 34.61%, NNNN belongs to the top of the industry, outperforming 98.38% of the companies in the same industry.

In the last couple of years the Operating Margin of NNNN has declined.

Looking at the Gross Margin, with a value of 52.78%, NNNN is in the better half of the industry, outperforming 77.48% of the companies in the same industry.

In the last couple of years the Gross Margin of NNNN has grown nicely.

		Industry Rank	Sector Rank
OM	34.61%
PM (TTM)	38.63%
GM	52.78%

OM growth 3Y-23.96%

OM growth 5YN/A

PM growth 3Y-20.3%

PM growth 5YN/A

GM growth 3Y7.8%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NNNN is creating value.

The number of shares outstanding for NNNN remains at a similar level compared to 1 year ago.

There is no outstanding debt for NNNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

NNNN has an Altman-Z score of 478.47. This indicates that NNNN is financially healthy and has little risk of bankruptcy at the moment.

NNNN's Altman-Z score of 478.47 is amongst the best of the industry. NNNN outperforms 99.82% of its industry peers.

There is no outstanding debt for NNNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	478.47

ROIC/WACC2.16

WACC7.2%

2.3 Liquidity

A Current Ratio of 10.71 indicates that NNNN has no problem at all paying its short term obligations.

NNNN's Current ratio of 10.71 is amongst the best of the industry. NNNN outperforms 80.18% of its industry peers.

NNNN has a Quick Ratio of 10.71. This indicates that NNNN is financially healthy and has no problem in meeting its short term obligations.

NNNN's Quick ratio of 10.71 is amongst the best of the industry. NNNN outperforms 80.18% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.71
Quick Ratio	10.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.70% over the past year.

Measured over the past years, NNNN shows a decrease in Earnings Per Share. The EPS has been decreasing by -2.10% on average per year.

The Revenue has grown by 21.95% in the past year. This is a very strong growth!

The Revenue has been growing by 22.72% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)5.7%

EPS 3Y-2.1%

EPS 5YN/A

EPS Q2Q%-77.56%

Revenue 1Y (TTM)21.95%

Revenue growth 3Y22.72%

Revenue growth 5YN/A

Sales Q2Q%-71.49%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 1040.33 indicates a quite expensive valuation of NNNN.

NNNN's Price/Earnings ratio is rather cheap when compared to the industry. NNNN is cheaper than 90.63% of the companies in the same industry.

NNNN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.98.

		Industry Rank	Sector Rank
PE	1040.33
Fwd PE	N/A

4.2 Price Multiples

90.81% of the companies in the same industry are more expensive than NNNN, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	658.43
EV/EBITDA	N/A

4.3 Compensation for Growth

NNNN has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NNNN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ANBIO BIOTECHNOLOGY LTD

NASDAQ:NNNN (6/27/2025, 8:00:02 PM)

After market: 31.01 -0.2 (-0.64%)

31.21

-2.43 (-7.22%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)04-28 2025-04-28

Earnings (Next)N/A N/A

Inst Owners4.94%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap1.37B

AnalystsN/A

Price TargetN/A

Short Float %0.05%

Short Ratio0.56

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	1040.33
Fwd PE	N/A
P/S	140.18
P/FCF	658.43
P/OCF	658.43
P/B	79.68
P/tB	79.68
EV/EBITDA	N/A

EPS(TTM)0.03

EY0.1%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.05

FCFY0.15%

OCF(TTM)0.05

OCFY0.15%

SpS0.22

BVpS0.39

TBVpS0.39

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	19.95%
ROE	21.95%
ROCE	19.67%
ROIC	15.54%
ROICexc	49.2%
ROICexgc	49.2%
OM	34.61%
PM (TTM)	38.63%
GM	52.78%
FCFM	21.29%

ROA(3y)32.84%

ROA(5y)N/A

ROE(3y)36.27%

ROE(5y)N/A

ROIC(3y)27.94%

ROIC(5y)N/A

ROICexc(3y)88.97%

ROICexc(5y)N/A

ROICexgc(3y)88.97%

ROICexgc(5y)N/A

ROCE(3y)35.37%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-23.96%

OM growth 5YN/A

PM growth 3Y-20.3%

PM growth 5YN/A

GM growth 3Y7.8%

GM growth 5YN/A

F-Score6

Asset Turnover0.52

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	250
Cash Conversion	N/A
Profit Quality	55.12%
Current Ratio	10.71
Quick Ratio	10.71
Altman-Z	478.47

F-Score6

WACC7.2%

ROIC/WACC2.16

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)57.33%

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)5.7%

EPS 3Y-2.1%

EPS 5YN/A

EPS Q2Q%-77.56%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)21.95%

Revenue growth 3Y22.72%

Revenue growth 5YN/A

Sales Q2Q%-71.49%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y1.76%

EBIT growth 3Y-6.69%

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y131.57%

FCF growth 3Y-20.76%

FCF growth 5YN/A

OCF growth 1Y131.57%

OCF growth 3Y-20.76%

OCF growth 5YN/A

ANBIO BIOTECHNOLOGY LTD (NNNN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens